Management Team

Shervin Korangy

President & CEO

Shervin brings nearly three decades of experience in general management, operations, finance, and investments across diverse industries, including healthcare, consumer products, industrial manufacturing, and financial services. Before joining BVI, he held senior executive roles at Novartis Group AG, one of the world’s largest healthcare companies, where he served as Global Head of Corporate Finance and in various country and regional commercial leadership positions.

Shervin began his career at The Blackstone Group, a leading alternative asset investment firm, spending 15 years across its Restructuring & Special Situations and Private Equity divisions, ultimately serving as Managing Director. He also co-founded Sight Sciences (Nasdaq: SGHT), a growth-stage medical device company transforming glaucoma and dry eye treatment.

He serves on several corporate and non-profit boards. He is a member of BVI’s Board of Directors (Compensation Committee), Fresenius Medical Care (NYSE: FMS / DAX: FME; Vice Chair, Nominating Committee; Member, Compensation Committee), and Hain Celestial (Nasdaq: HAIN; Chair, Compensation Committee; Member, Nominating and Governance Committee). He is also on the board of the Ophthalmology Foundation, a non-profit advancing ophthalmic education in underserved regions, and serves on The Wharton School’s Undergraduate Board and Leadership Advisory Board.

Shervin holds a B.S. in Economics from The Wharton School of the University of Pennsylvania.

Todd Patriacca

Chief Financial Officer

Todd Patriacca brings more than 25 years of financial experience with an extensive background in handling complex matters including M&A, IPOs, debt and equity financing, commercial agreements, financial accounting and controls, compliance, information systems, and investor relations. Prior to BVI, Todd was Chief Financial Officer & Treasurer at Altra Industrial Motion, a publicly traded global industrial manufacturer of motion control, power transmission, and automation products with 9,000+ employees and sales in 100+ countries. He was a core member of an executive team that successfully executed a strategy to grow the business from $300 million to $2 billion in annual revenues through a combination of organic growth and strategic M&A. In addition, Todd has affiliations at the Massachusetts Society of Certified Public Accountants, American Institute of Certified Public Accounts, Chartered Global Management Accountant, and Manufacturers Alliance (MAPI) CFO Council. Todd holds two Masters’s degrees in Business Administration and Science in Accounting from Boston Northeastern University.

Andrew Chang

Chief Commercial Officer

Andrew Chang brings over 20 years of commercial leadership experience in the ophthalmic medical device and pharmaceutical sectors, having held senior roles across some of the industry’s most recognized global organizations.

Chang began his career in finance and early-stage business roles before transitioning into the ophthalmic space, where he held progressive commercial leadership positions at ISTA Pharmaceuticals and later Bausch + Lomb. During his time at ISTA, he helped drive the successful introduction of multiple ophthalmic pharmaceutical products. Following the acquisition of ISTA by Bausch + Lomb, he took on broader responsibilities at OptiMedica which sold to Abbott Medical Optics shortly after. Eventually he served as General Manager and Senior Vice President for Bausch + Lomb Surgical, overseeing U.S. sales, marketing, operations, and business development.

He later joined ZEISS Medical Technology, where he served as President of Carl Zeiss Meditec USA, Inc. and Head of Global Sales for Ophthalmic Devices. In this role, he led global commercial strategy and market execution across a broad portfolio of diagnostic and surgical technologies, playing a key role in expanding ZEISS’s global footprint and driving sustained commercial growth.

Beyond his executive leadership roles, Andrew is a passionate advocate for innovation in ophthalmology. He currently serves on industry and advisory boards the ASCRS Foundation, the Ophthalmology Foundation, Medical Device Manufacturers Association (MDMA), CEDARS/ASPENS Industry Committee, AECOS Executive Committee, Ophthalmic World Leaders (OWL), EyeSustain and is a founding member of the Vanguard Ophthalmology Society. In the past he served on the board of MicroOptx, President and board of FCI Ophthalmics Inc / FCI SAS, and American Glaucoma Society Foundation.

Andrew Chang earned his Bachelor of Science degree in Management from Rutgers University – Newark

Andrew (Andy) Dawson

Chief People Officer and Head of Corporate Affairs

Andrew (Andy) Dawson brings more than 20 years of experience in human resource strategy and management with some of the world’s leading Healthcare and Biopharma companies. Mr. Dawson started his career in Human Resources with Eli Lilly and Company and continued to grow his career through progressive HR leadership roles at both Novartis and Roche around the globe, including the formation of the Vaccines and Diagnostics Business following Novartis’ acquisition of Chiron. Upon joining Shire in 2014, he played a key leadership role in re-imagining the global HR function during a significant time of transformation. While there, he helped lead the organization through significant change and growth following numerous mergers and acquisitions including the leadership of the new global site strategy following the $32bn acquisition of Baxalta, and the design and execution of the new organization design for the expanded company. Following this, Mr Dawson held roles of increasing scope and responsibility at TripAdvisor and most recently leading the Human Resources function for emerging, pre-commercial companies in the Biotech space. Mr Dawson is a member of the Forbes HR Leadership Council, serves on the advisory board(s) for LEAP HR and BioPharma Talent / CBI. Mr Dawson holds a Masters Degree in Human Resources Management and Development from the University of Salford (Manchester, UK).

Mikhail Boukhny

Senior Vice President of Research and Development

Mikhail Boukhny brings over 25 years of leadership experience in Surgical Ophthalmology. Until 2018 he lead Alcon’s Surgical Instrumentation R&D in Cataract, Vitreoretinal, Refractive and Diagnostics areas. Mikhail has grown through the ranks at Alcon, developing many breakthrough products, including Torsional ultrasound and Centurion Vision System. He combines a  deep understanding of unmet clinical and business needs with the ability to bring breakthrough innovation to commercial success as well as to create strong teams. Mikhail holds over 70 patents; while at Alcon he was repeatedly recognized for his accomplishments,  including the prestigious Novartis VIVA award. Most recently Mikhail was leading Zeiss MediTec Surgical R&D, Ophthalmology where, in addition to equipment, he was responsible for IOLs, IOL delivery systems and OVDs. Dr. Boukhny received his M.S. in Biophysics from the Moscow Institute of Physics and Technology and his Ph.D. in Physics from the University of Virginia.

Jean-Nicolas Fassin

Vice President, Business Development & General Counsel

Jean-Nicolas (“JN”) Fassin has 15 years of experience in M&A, corporate finance, strategy and law. He joined the BVI leadership team following the acquisition of PhysIOL^® by BVI in late 2018. Prior to joining PhysIOL® in 2017, JN was a Senior Manager at BDO Corporate Finance in Belgium advising clients on small- and mid-sized M&A transactions, valuation and financial due diligence across various industries.  He also worked as management consultant at McKinsey & Company focusing on strategy assignments and as lawyer in top tier law firms advising clients on M&A, litigation and corporate law matters.  He has an MBA from London Business School, an LLM from Columbia Law School and is a graduate of Sciences Po Paris and the University of Liège, Faculty of Law.

Christine Lucas

Senior Vice President, Global Operations and Technology

Christine Lucas brings more than 20 years of progressive experience in global operations including manufacturing, supply chain and engineering. Serving most recent as Vice President of Operations at Zimmer Biomet Holding, Inc., where she was focused was on end-to-end global supply chain, operations excellence and new product introductions. Christine was responsible for leading the Dental business unit supply chain organization including its global distribution and manufacturing footprint. Prior to Zimmer, Christine held a variety of operating roles at Biomet 3i, Boston Scientific and King Systems. Christine earned an Associate of Science degree in Manufacturing and Mechanical Engineering from the Institute Universitaire de Technologie in France and a Bachelor of Science degree in Biomedical Engineering from the Université de Technologie in Compiègne, France.

Devang V. Shah, Ph.D.

Senior Vice President, Business Operations and Quality Assurance

Devang Shah brings to BVI over 15 years of experience building and leading teams in medical device R&D, Strategy and Business Development. Throughout his tenure at Bard, Devang held roles of increasing responsibility focused on creating and executing against product development pipelines that addressed significant unmet clinical needs and delivered organic revenue growth. While co-leading Bard’s Tissue Regeneration Franchise, Devang and his team supported the development and commercial launch of innovative new product lines which have generated organic revenues of >$100 million. His career began at Boston Scientific as a Consultant in the Urology & Women’s Health Division.  He earned a Bachelor of Science degree in Biomedical Engineering from Worcester Polytechnic Institute followed by a Master of Engineering in Chemical Engineering from Tufts University. He subsequently earned a Ph.D. in Molecular Biology from Northeastern University and an MBA from the MIT Sloan School of Management.